The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.
 
Konrad Friedrich Klinghammer
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD Oncology
 
Thomas Christoph Gauler
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche
 
Carmen Stromberger
Honoraria - Bristol-Myers Squibb; Merck Serono; Promedior
Consulting or Advisory Role - Bristol-Myers Squibb
 
Grzegorz Kofla
No Relationships to Disclose
 
Maike de Wit
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Gilead Sciences; Novartis; Pierre Fabre
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Ipsen; Janssen; Medac; MSD; Promedior; Roche; Sanofi; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genzyme (Inst); Ipsen (Inst); Janssen (Inst); MSD (Inst); Noona Healthcare (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Pfizer; Takeda
 
Johannes Gollrad
No Relationships to Disclose
 
Izabella Rauer
No Relationships to Disclose
 
Peter Martus
No Relationships to Disclose
 
Inge Tinhofer
Honoraria - Merck KGaA
Consulting or Advisory Role - Merck Serono
 
Volker Budach
Honoraria - Accuray; Merck Serono; Varian Medical Systems
Consulting or Advisory Role - Accuray; Merck Serono
 
Ulrich Keilholz
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Glycotope GmbH; Merck KGaA; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology; pfizer
Speakers' Bureau - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer Schering Pharma; Ipsen; Merck Serono; MSD Oncology; Pierre Fabre
 
Susen Burock
No Relationships to Disclose